agent

(redirected from Erythropoiesis-stimulating agent)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

agent

a person representing a business concern, esp a travelling salesman

Agent

 

in Soviet civil law, a party in a contract of agency. The agent’s duties include the performance of specified legal acts, for example, contracts of sale and management of property, in the name of and on the account of a principal party. The agent may be a legally competent (sui juris) citizen or a legal person (if this is allowed by the latter’s charter or statute). The actions performed by the agent directly generate, change, or extinguish rights and obligations of the principal.

The agent is bound to perform the agency in exact conformity with the principal’s instructions, carry out the agency personally, although in instances provided for by law the responsibilities may be transferred to another person (art. 68 of the RSFSR Civil Code), inform the principal upon demand of progress in performing the agency, submit a report on performance of the agency, and transfer to the principal any property obtained in connection with performance of the agency.

agent

One who is empowered to enter into binding transactions on behalf of another (usually called the principal).

agent

(networking)
In the client-server model, the part of the system that performs information preparation and exchange on behalf of a client or server. Especially in the phrase "intelligent agent" it implies some kind of automatic process which can communicate with other agents to perform some collective task on behalf of one or more humans.

agent

A software routine that waits in the background and performs an action when a specified event occurs. For example, agents could transmit a summary file on the first day of the month or monitor incoming data and alert the user when a certain transaction has arrived. Agents are also called "intelligent agents," "personal agents" and "bots." See mobile agent, bot and workflow.
References in periodicals archive ?
There is also a lack of data directly comparing the efficacy of the currently available erythropoiesis-stimulating agents.
Information on erythropoiesis-stimulating agents (ESA) (marketed as Procrit, Epogen, and Aranesp).
It is necessary to conduct new clinical studies that will include a larger number of patients and assess whether the results obtained in this study are specific for erythropoietin [beta] or the same results can be obtained when administering other erythropoiesis-stimulating agents.
Articles involving erythropoiesis-stimulating agents (ESAs) were reviewed in order to search for any link between pharmaceutical industry funding and basic scientific research results.
To treat anemia successfully in veterans, physicians administer erythropoiesis-stimulating agents (ESAs).
Erythropoiesis-stimulating agents (ESAs) stimulate bone marrow to increase the production of red blood cells, lowering the need for blood transfusions during chemotherapy in cancer patients.
Management of anemia: A critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
The blockbuster drugs are part of a class called erythropoiesis-stimulating agents (ESAs), which are approved for treating patients with kidney disease and cancer.
WASHINGTON -- Limiting the use of erythropoiesis-stimulating agents in patients with chemotherapy induced anemia would greatly increase demand for blood products and impose considerable pressure on the available U.
These drugs are called erythropoiesis-stimulating agents (ESAs).
These drugs, known as erythropoiesis-stimulating agents (ESAs), have been shown to increase risk of "serious and life-threatening side effects," including increased risk of blood clots, heart attacks, strokes, heart failure, and faster tumor growth in some cancers, as well as an increased risk of death.
The results presented at EHA confirm and extend previously reported results across the lower-risk MDS patient subpopulations, showing erythroid responses regardless of prior use of erythropoiesis-stimulating agents, baseline erythropoietin levels, and ring sideroblast status.

Full browser ?